Planta Med 2006; 72(3): 228-233
DOI: 10.1055/s-2005-916212
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Selective Inhibition of COX-2 by a Standardized CO2 Extract of Humulus lupulus in vitro and its Activity in a Mouse Model of Zymosan-Induced Arthritis

Sander Hougee1 , Joyce Faber1 , Annemarie Sanders1 , Wim B. van den Berg2 , Johan Garssen1 , 3 , H. Friso Smit1 , Maarten A. Hoijer1
  • 1Numico Research, Wageningen, The Netherlands
  • 2Department of Experimental Rheumatology & Advanced Therapeutics, University Medical Center Nijmegen St. Radboud, Nijmegen, The Netherlands
  • 3Department of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands
Further Information

Publication History

Received: December 16, 2004

Accepted: August 19, 2005

Publication Date:
05 January 2006 (online)

Preview

Abstract

A standardized CO2 extract from Humulus lupulus L. (hop extract) was investigated for its selective COX-1/2 inhibitory properties. An in vitro model of inflammation using lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMC) was used as a model to investigate the effect of hop extract on PGE2 production. COX-1/2 selective inhibition by the hop extract was investigated in a COX-1 whole blood assay (WBA) and a COX-2 WBA. To evaluate the in vivo activity of hop extract, it was administered orally to C57BL/6 mice in which inflammation of the right joint was induced by injecting zymosan intra-articularly. Ex vivo PGE2 production of LPS-stimulated blood cells was determined. Also, the effect of hop extract on healthy and arthritic cartilage was investigated as well as effects on inflammatory joint swelling. Hop extract inhibited PGE2 production by LPS-stimulated PBMC without compromising the metabolic activity of these cells. Furthermore, hop extract showed a decline in PGE2 production in the COX-2 whole blood assay (WBA) with an IC50 of 20.4 μg/mL, while in the COX-1 WBA no inhibition of PGE2 production was observed. This indicates a COX-2 selective inhibition. The COX-1 inhibitor SC-560 inhibited PGE2 production in the COX-1 WBA but not in the COX-2 WBA. At 2 μM, celecoxib inhibited PGE2 production in the COX-2 WBA by 92 % and in the COX-1 WBA by 50 %. When hop extract was administered orally to C57BL/6 mice in which joint inflammation was induced with zymosan, PGE2 production in ex vivo LPS-stimulated whole blood was significantly decreased by 24 %, suggesting that hop extract becomes bioavailable. Furthermore, oral administration of hop extract showed no negative or positive effects on healthy cartilage proteoglycan synthesis, or on zymosan-induced arthritic cartilage proteoglycan synthesis. However, no effect of oral administration of 1.25 mg hop extract daily was observed on joint swelling. In conclusion, this standardized CO2 extract of Humulus lupulus could be a useful agent for intervention strategies targeting inflammatory disorders and/or inflammatory pain.

References

Sander Hougee

Numico Research

P.O. Box 7005

6700 CA Wageningen

The Netherlands

Email: Sander.Hougee@Numico-Research.nl